Fruzaqla Approved in Canada for Metastatic Colorectal Cancer
FRUZAQLA (fruquintinib) is now approved in Canada for metastatic colorectal cancer (mCRC) patients who have exhausted standard therapies. This new oral VEGFR inhibitor significantly improves survival in patients previously treated with multiple regimens, offering a new hope.
Fruzaqla Approved in Canada for Metastatic Colorectal Cancer Read More »